FOXO4-DRI

FOXO4-DRI is a synthetic peptide that disrupts the FOXO4-p53 interaction inside senescent ('zombie') cells, triggering their selective apoptosis. It was developed by Peter de Keizer's lab at Erasmus University and is one of the most-discussed peptide-based senolytics — compounds that selectively kill senescent cells believed to drive many features of aging. The original 2017 paper in Cell received enormous attention for showing improvements in fur density, kidney function, and physical activity in aged mice. It is sold strictly for laboratory research.

As you age, your tissues accumulate 'zombie cells' — cells that should have died but instead linger around secreting inflammatory signals that damage nearby healthy tissue. FOXO4-DRI is a research peptide designed to kill these zombie cells selectively. In aged mice, treatment restored fur thickness, improved kidney markers, and increased physical activity — results that made headlines and gave senolytics a major popular moment. It is one of the most ambitious peptides in the longevity research space.

Senescent cells survive by depending on a FOXO4-p53 interaction that suppresses apoptosis. FOXO4-DRI is a D-retro-inverso peptide (more stable than natural L-amino acid versions) that competes with native FOXO4, freeing p53 to trigger apoptosis specifically in senescent cells. Healthy non-senescent cells are largely unaffected because they do not depend on this interaction for survival.

Specialized senolytic. Targets and eliminates senescent ('zombie') cells causing inflammation.

1. FOXO4-DRI
2. Mitochondrial and cellular-maintenance pathways
3. NAD+ availability, mitohormesis or senescent-cell signalling
4. Cellular-ageing and metabolic-resilience endpoints

A plain-English read on how much published evidence currently exists for FOXO4-DRI. These ratings describe the volume and maturity of the literature — not effectiveness, safety, or suitability for any use.

Current limitations: most compounds in this category are studied in preclinical or small-sample settings. Absence of large controlled human trials is the single biggest limitation to keep in mind when reading any summary of FOXO4-DRI.

Lyophilized compounds are supplied as a dry powder. Concentration is simply the total amount in the vial divided by the volume of bacteriostatic water added:

Concentration (mg/mL) = total mg in vial ÷ mL of diluent added

Commonly supplied vial sizes

25mg vial

Worked concentration example

25mg + 5mL BAC water → 5mg/mL On U-100 insulin syringe:

• • 100 units = 5mg

Run your own numbers with the reconstitution calculator — it converts vial size and diluent volume into mg/mL and mcg/mL.

The figures below are reported here descriptively, because they are the values most frequently cited in publicly available research literature and reference material. They are not instructions, not a protocol, and not a recommendation. These compounds are supplied for laboratory research use only and are not approved by the FDA for human consumption.

Commonly cited amounts

5mg daily subcutaneous for 5 days (pulse protocol)

Commonly cited frequency

Daily during the 5-day pulse

Commonly cited study duration

5-day pulse, repeated 1–2× per year

Peptides are supplied freeze-dried because peptide bonds degrade far faster in solution than in a dry state. Understanding storage is part of understanding why the powder form exists at all.

• •Lyophilized powder: stored refrigerated, typically stable for months to years.
• •Reconstituted solution: refrigerated at 2–8°C, generally discussed as stable for roughly 30–60 days.
• •Heat and direct light accelerate degradation — vials are kept cool and dark.
• •Reconstituted material is not re-frozen; ice crystal formation disrupts peptide structure.
• •Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what allows multi-day storage after reconstitution.

More detail in the storage & handling guide and how peptide quality is evaluated.

• •Senescent cell clearance in aged tissue
• •Fur and skin regeneration in mice
• •Kidney function in aged animals
• •Chemotherapy-induced senescence research
• •Senolytic pharmacology and combination therapy

FOXO4-DRI is a longevity-forum and biohacker favorite. Discussion centers on the de Keizer mouse study, comparisons to small-molecule senolytics like dasatinib + quercetin and fisetin, and the practical difficulties of synthesizing a stable D-retro-inverso peptide. Forum protocols are highly cautious and typically infrequent (every few weeks or months) given the powerful apoptotic mechanism.

“A peptide that tells zombie cells to die.”

FOXO4-DRI is sometimes discussed alongside fisetin, quercetin, or dasatinib in 'senolytic stack' protocols — combining peptide and small-molecule mechanisms. Combinations are theoretical and not based on published clinical data.

FOXO4-DRI is a synthetic D-retro-inverso peptide senolytic that selectively kills senescent cells by disrupting the FOXO4-p53 interaction. The original 2017 mouse study showed remarkable age-related improvements. It remains preclinical and is sold for laboratory research only.